Quest Diagnostics will launch an FDA-cleared Roche pTau217 Alzheimer’s blood test and a new multi-biomarker LDT, expanding its AD-Detect portfolio for improved diagnostic accuracy in late 2026.
Epredia will incorporate Leeds NHS Trust’s TANGO quality control technology into pathology slides, aiming to enhance staining consistency for digital pathology and AI diagnostics. Integration is set to begin in late 2026.
Proscia’s Concentriq AP-Dx digital pathology platform has received FDA 510(k) clearance for compatibility with the Leica Aperio GT 450 DX scanner and a Predetermined Change Control Plan to streamline future updates.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
Leica Biosystems received FDA 510(k) clearances for AI-assisted quality control software and two digital pathology scanners, including the first standalone tool to automate QC for digital slides in clinical workflows.
Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
The company showcased its latest automation and informatics platforms designed to improve laboratory efficiency and diagnostic accuracy.
USC researchers report that two blood tests, Lumipulse G p-tau217/β-Amyloid 1-42 and PrecivityAD2, can accurately detect Alzheimer’s pathology in patients with Down syndrome.
SCIEX has launched the ExionLC MD system and updated SCIEX OS software, featuring workflow automation and high-performance UHPLC, to help clinical labs improve productivity, as announced at the ADLM meeting.
Astorg has completed its acquisition of Thermo Fisher’s global microbiology business, establishing an independent diagnostics company. Dirk Bontridder has been named CEO.
QIAGEN has received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, enabling detection of 20 pathogens and 10 antimicrobial resistance markers from positive blood cultures in about one hour.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.